Moreover, the strong expression of CD6 ligands on cancer cells suggests that lymphocyte-engaging therapies such as anti-CD6 should be advanced into clinical trials based on the findings that CD6 blockade concurrently reduces T-cell autoimmunity and increases T-cell and NK-cell cytotoxicity. The gene discussed is CD6; the disease is Autoimmunity.